OncoMatch/Clinical Trials/NCT06293014
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Is NCT06293014 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TAS-102+bevacizumab and Standard chemotherapy+bevacizumab for colorectal cancer.
Treatment: TAS-102+bevacizumab · Standard chemotherapy+bevacizumab — This study is a randomized, controlled, open-label, multicentre clinical study. This study is designed to evaluate the efficacy and safety of TAS-102 combined with bevacizumab as second-line maintenance therapy versus standard chemotherapy combined with bevacizumab as second-line continuous therapy in advanced colorectal cancer after second-line induction therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (FOLFOX, FOLFIRI, CAPEOX) — second-line induction therapy combined with bevacizumab
After receiving 12 weeks of standard chemotherapy (FOLFOX, FOLFIRI, or CAPEOX) combined with bevacizumab second-line induction therapy, the patients are confirmed as CR, PR, or SD according to RECIST 1.1 criteria
Cannot have received: antineoplastic agent (TAS-102)
Prior treatment with TAS-102
Lab requirements
Blood counts
Adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Kidney function
Adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Liver function
Adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Adequate major organ function (no medication for blood component, cell growth factor correction therapy is allowed within 14 days before randomization)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify